|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.75 CNY | -0.53% |
|
-2.77% | -3.41% |
| 01-22 | Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95% | MT |
| 01-15 | Gan & Lee Pharmaceuticals Gets EU Approval for Insulin Injection; Shares Up 4% | MT |
Published on 12/16/2024
Gan & Lee Pharmaceuticals removed
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Select your edition
All financial news and data tailored to specific country editions
